Journal article
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute …
Authors
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S
Journal
New England Journal of Medicine, Vol. 369, No. 14, pp. 1327–1335
Publisher
Massachusetts Medical Society
Publication Date
October 3, 2013
DOI
10.1056/nejmoa1305889
ISSN
0028-4793